Related Experiment Video
Updated: Apr 13, 2026

Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Insights
This corrigendum corrects the affiliation of Mr. Nobuo Shirahashi in the NAGOYA HEART Study appendix. The corrected affiliation is Novartis Pharma KK and Osaka City University Medical School.
Area of Science:
- Cardiology
- Clinical Trials
- Hypertension Management
Context:
- The NAGOYA HEART Study investigated valsartan versus amlodipine in hypertensive patients with glucose intolerance.
- Accurate author affiliations are crucial for scientific integrity and collaboration.
Purpose:
- To correct an error in the listed affiliation of Mr. Nobuo Shirahashi.
- To ensure accurate attribution and provide correct contact information for future reference.
Summary:
- A correction is issued for the NAGOYA HEART Study manuscript.
- Mr. Nobuo Shirahashi's affiliation has been updated to Novartis Pharma KK and Osaka City University Medical School.
Impact:
- Ensures the accuracy of the published scientific record.
- Facilitates correct identification of research contributions and institutional affiliations.
Abstract:
Corrigendum to "Rationale and design of the NAGOYA HEART Study: Comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance" [J. Cardiol. 56 (2010) 111–117] The authors of the manuscript would like to correct affiliation of Mr. Nobuo Shirahashi, who was mentioned in the Appendix section of this article. The correct affiliation of Mr. Shirahashi was Novartis Pharma KK and Department of Preventive Medicine and Environmental Health, Osaka City University Medical School, Osaka, Japan.
Related Concept Videos
Proofreading
Proofreading
Errors During Replication are Corrected by the DNA Polymerase...
Proofreading
Clot Retraction and Fibrinolysis
NMR Spectrometers: Resolution and Error Correction
Accuracy and Errors in Hypothesis Testing
In hypothesis testing, the probability of making a Type I error, denoted as α, is commonly set at 0.05. This significance level indicates a 5%...

